Proton pump inhibitors in pediatrics;Inhibiteurs de la pompe a protons en pediatrie

Archives de Pediatrie

Volumn 6, Issue 6, 1999, Pages 650-656

  Faure, C ^a   Pelatan, C ^a   Languepin, J ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Child; Esophagitis; Peptic ulcer; Proton pump; Ulcer

Indexed keywords

ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

CHILD; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERANCE; DRUG USE; HUMAN; PEPTIC ULCER; REVIEW; STOMACH ACID SECRETION; TREATMENT INDICATION;

EID: 0033149930     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(99)80298-X     Document Type: Article

References (30)

1. Yahav J. Development of the parietal cells, acid secretions and response to secretagogues. In: Lcbcnthal E, cd. Human Gastrointestinal Development. New York: Raven Press; 1989. p. 341-51.
2. E édition. Paris: Flammarion Médecine-Sciences; 1999 [à paraître].
3. Lewin MJM. Les inhibiteurs de la pompe à protons gastrique: Mode d'action et intérêt thérapeutique. Med Sci 1995; 11: 62-71.
4. Kelly EJ, Brownlee KG. When is the fetus first capable of gastric acid, intrinsic factor and gastrin secretion? Biol Neonate 1993; 63: 153-6.
5. Maton PM. Omeprazole. N Engl J Med 1991; 324: 965-75.
6. Anderson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
7. Kato S, Shibuya H, Hayashi Y, Tseng SW, Nagakawa H, Ohi R. Effectiveness and pharmacokinetics of omeprazole in children with refractory duodenal ulcer. J Pediatr Gastroenterol Nutr 1992; 15: 184-8.
8. Kato S, Ebina K, Fuji K, Chiba H, Nakagawa H. Effect of omaprazole in the treatment of refractory acid-related disease in childhood: Endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996; 128: 415-21.
9. Dupont C, Pariente-Kayat A, Benhamou PH, D'Athis P, Soulaines P, Sallerin V, et al. Effet antisécrétoire du lansoprazole en pédiatrie: Étude pharmacocinétique et ph-métrique. Congrès du Groupe Francophone D'hépato-gastroentérologie et Nutrition. Pise; 1997.
10. Jacqz-Aigrain E, Bellaiche M, Faure C, André J, Rohrlich P, Baudouin V, et al. Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 1994; 47: 181-5.
11. Gunasekaran TS, Hassal E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123: 148-54.
12. Hassal E, Israel DM, Sheperd R, Radke M, Dalvag A, Junghard O, et al. Omeprazole for chronic erosive esophagitis in children: A multicenter study of dose requirements for healing. Gastroenterology 1997; 112: A143.
13. Faure C, Jacqz-Aigrain E, Bellaiche M, Burtin P, Mougenot JF, Cézard JP, et al. Intravenous omeprazole in children: Effectiveness and pharmacology. Gastroenterology 1994; 106: A76.
14. Cucchiara S, Minella R, Campanozzi A, Salvia G, Borelli O, Ciccimarra E, et al. Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Dig dis Sci 1997; 42: 293-9.
15. Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995; 149: 267-71.
16. Cucchiara S, Minella R, Iervolino, Franco MT, Campanozzi A, Franceschi M, et al. Omeprazole and high dose ranitidine in the treatment of refractory esophagitis. Arch dis Child 1993; 69: 655-9.
17. Dohil R, Israel DM, Hassal E. Effective 2-week therapy for helicobacter pylori eradication in children. Am J Gastroenterol 1997; 97: 244-7.
18. Kato S, Takeyama J, Ebina K, Naganuma H. Omeprazole based dualand triple regimen for helicobacter pylori eradication in children. Pediatrics 1997; 100: 1-5.
19. Gustavson LE. Effects of omeprazole on concentrations of clarythromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39; 2078-83.
20. Castot A, Bidault I, Dahan R, Efthymiou ML. Bilan des effets inattendus et toxiques de l'oméprazole au cours des 22 premiers mois de commercialisation. Thérapie 1993; 48: 469-74.
21. Melville C, Shah A, Matthew D, Milla P. Electrolyte disturbance with omeprazole therapy. Eur J Pediatr 1994; 153: 49-51.
22. Joelson S, Joelson IB, Lundborg P, Walan A, Wallander MA. Safety experience from long term treatment with omeprazole. Digestion 1992; 51 (suppl 1): 93-101.
23. Soulé JC. Reflux gastro-œsophagien. Les thérapeutiques médicales majeures: Efficacité et risques. Presse Méd 1997; 26: 1257-63.
24. Faure C, Besnard M, Cezard JP. Traitement du reflux gastro-œsophagien. Arch Pediatr 1995; 2: 263-6.
25. Vandenplas Y, Belli D, Blecker U, Benhamou PH, Cadranel S, Cezard JP, et al. A critical appraisal of current management practices for infant regurgitation. Recommandations from a working party. Eur J Pediatr 1997; 156: 343-57.
26. Bohmer CJM, Niezen-de Boer MC, Klinkenberg-Knol EC, Meuwissen SGM. Omeprazole: Therapy of choice in institutionalized intellectually disabled children. Gastroenterology 1998; 115: A763.
27. Sharma V K, Ugheoke E A, Vasudeva R, Howden CW. Lansoprazole effectively supresses intragastric acidity when administered via gastrostomy as intact granules in orange juice. Gastroenterology 1998; 115: A73.
28. Oderda G, Chiorboli E, Rapa A, Haitink O, Bona G. Inhibition of gastric acidity in children by lansoprazole in granules. Gastroenterology 1998; 115: A74.
29. Evenepoel P, Claus D, Geypens B, Maes B, Hiele M, Rutgeerts P, et al. Evidence for impaired assimilation and increased colonie fermentation of protein, related to gastric acid suppression therapy. Aliment Pharmacol Ther 1998; 12: 1011-9.
30. Haga Y, Nakatsura T, Shibata Y, Sameshima H, Nakamura Y, Tanimura M et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig dis Sci 1998; 43: 253-7.